These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26934697)

  • 41. High-Content Phenotypic Screen of a Focused TCAMS Drug Library Identifies Novel Disruptors of the Malaria Parasite Calcium Dynamics.
    Chia W; Gomez-Lorenzo MG; Castellote I; Tong JX; Chandramohanadas R; Thu Chu TT; Shen W; Go ML; de Cozar C; Crespo B; Almela MJ; Neria-Serrano F; Franco V; Gamo FJ; Tan KSW
    ACS Chem Biol; 2021 Nov; 16(11):2348-2372. PubMed ID: 34609851
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiplasmodial profile of selected compounds from Malaria Box: in vitro evaluation, speed of action and drug combination studies.
    de Souza GE; Bueno RV; de Souza JO; Zanini CL; Cruz FC; Oliva G; Guido RVC; Aguiar ACC
    Malar J; 2019 Dec; 18(1):447. PubMed ID: 31888654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dephospho-Coenzyme A Kinase Is an Exploitable Drug Target against Plasmodium falciparum: Identification of Selective Inhibitors by High-Throughput Screening of a Large Chemical Compound Library.
    Nurkanto A; Imamura R; Rahmawati Y; Prabandari EE; Waluyo D; Annoura T; Yamamoto K; Sekijima M; Nishimura Y; Okabe T; Shiba T; Shibata N; Kojima H; Duffy J; Nozaki T
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0042022. PubMed ID: 36314787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nima- and Aurora-related kinases of malaria parasites.
    Carvalho TG; Doerig C; Reininger L
    Biochim Biophys Acta; 2013 Jul; 1834(7):1336-45. PubMed ID: 23462523
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In silico multiple-targets identification for heme detoxification in the human malaria parasite Plasmodium falciparum.
    Phaiphinit S; Pattaradilokrat S; Lursinsap C; Plaimas K
    Infect Genet Evol; 2016 Jan; 37():237-44. PubMed ID: 26626103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum.
    Vaidya AB; Morrisey JM; Zhang Z; Das S; Daly TM; Otto TD; Spillman NJ; Wyvratt M; Siegl P; Marfurt J; Wirjanata G; Sebayang BF; Price RN; Chatterjee A; Nagle A; Stasiak M; Charman SA; Angulo-Barturen I; Ferrer S; Belén Jiménez-Díaz M; Martínez MS; Gamo FJ; Avery VM; Ruecker A; Delves M; Kirk K; Berriman M; Kortagere S; Burrows J; Fan E; Bergman LW
    Nat Commun; 2014 Nov; 5():5521. PubMed ID: 25422853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasmodium falciparum encodes a conserved active inhibitor-2 for Protein Phosphatase type 1: perspectives for novel anti-plasmodial therapy.
    Fréville A; Cailliau-Maggio K; Pierrot C; Tellier G; Kalamou H; Lafitte S; Martoriati A; Pierce RJ; Bodart JF; Khalife J
    BMC Biol; 2013 Jul; 11():80. PubMed ID: 23837822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-Content Screening of the Medicines for Malaria Venture Pathogen Box for Plasmodium falciparum Digestive Vacuole-Disrupting Molecules Reveals Valuable Starting Points for Drug Discovery.
    Tong JX; Chandramohanadas R; Tan KS
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311064
    [No Abstract]   [Full Text] [Related]  

  • 49. Epistasis studies reveal redundancy among calcium-dependent protein kinases in motility and invasion of malaria parasites.
    Fang H; Gomes AR; Klages N; Pino P; Maco B; Walker EM; Zenonos ZA; Angrisano F; Baum J; Doerig C; Baker DA; Billker O; Brochet M
    Nat Commun; 2018 Oct; 9(1):4248. PubMed ID: 30315162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The potent antiplasmodial calmodulin-antagonist trifluoperazine inhibits plasmodium falciparum calcium-dependent protein kinase 4.
    Cavagnino A; Rossi F; Rizzi M
    Protein Pept Lett; 2011 Dec; 18(12):1273-9. PubMed ID: 21787279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones.
    Geyer JA; Keenan SM; Woodard CL; Thompson PA; Gerena L; Nichols DA; Gutteridge CE; Waters NC
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1982-5. PubMed ID: 19250824
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Whole-Cell Phenotypic Screening of Medicines for Malaria Venture Pathogen Box Identifies Specific Inhibitors of
    Patra AT; Hingamire T; Belekar MA; Xiong A; Subramanian G; Bozdech Z; Preiser P; Shanmugam D; Chandramohanadas R
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antimalarial drug targets and drugs targeting dolichol metabolic pathway of Plasmodium falciparum.
    Qidwai T; Priya A; Khan NA; Tripathi H; Khan F; Darokar MP; Pal A; Bawankule DU; Shukla RK; Bhakuni RS
    Curr Drug Targets; 2014 Apr; 15(4):374-409. PubMed ID: 23848395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes.
    Vidadala RS; Ojo KK; Johnson SM; Zhang Z; Leonard SE; Mitra A; Choi R; Reid MC; Keyloun KR; Fox AM; Kennedy M; Silver-Brace T; Hume JC; Kappe S; Verlinde CL; Fan E; Merritt EA; Van Voorhis WC; Maly DJ
    Eur J Med Chem; 2014 Mar; 74():562-73. PubMed ID: 24531197
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A class of tricyclic compounds blocking malaria parasite oocyst development and transmission.
    Eastman RT; Pattaradilokrat S; Raj DK; Dixit S; Deng B; Miura K; Yuan J; Tanaka TQ; Johnson RL; Jiang H; Huang R; Williamson KC; Lambert LE; Long C; Austin CP; Wu Y; Su XZ
    Antimicrob Agents Chemother; 2013 Jan; 57(1):425-35. PubMed ID: 23129054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Viability Screen of LOPAC
    Tong JX; Ang SEL; Tan EHN; Tan KSW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antimalarial drugs and drug targets specific to fatty acid metabolic pathway of Plasmodium falciparum.
    Qidwai T; Khan F
    Chem Biol Drug Des; 2012 Aug; 80(2):155-72. PubMed ID: 22487082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Plasmodium falciparum cytoplasmic translation apparatus: a promising therapeutic target not yet exploited by clinically approved anti-malarials.
    Sheridan CM; Garcia VE; Ahyong V; DeRisi JL
    Malar J; 2018 Dec; 17(1):465. PubMed ID: 30541569
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.
    Silveira FF; de Souza JO; Hoelz LVB; Campos VR; Jabor VAP; Aguiar ACC; Nonato MC; Albuquerque MG; Guido RVC; Boechat N; Pinheiro LCS
    Eur J Med Chem; 2021 Jan; 209():112941. PubMed ID: 33158577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 7H-Pyrrolo[2,3-d]pyrimidine-4-amines as Potential Inhibitors of Plasmodium falciparum Calcium-Dependent Protein Kinases.
    Seanego TD; Chavalala HE; Henning HH; de Koning CB; Hoppe HC; Ojo KK; Rousseau AL
    ChemMedChem; 2022 Nov; 17(22):e202200421. PubMed ID: 36106757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.